Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Potassium iodide goes nuclear

This article was originally published in The Tan Sheet

Executive Summary

State and local governments should make potassium iodide pills available to people age 40 and younger living near nuclear power plants, especially children and pregnant and lactating women, according to a report from the National Academies' Research Council to be published in early 2004. Distribution and Administration of Potassium Iodide in the Event of a Nuclear Incident also calls on the federal government to provide financial support to states to help implement distribution plans and keep back-up stores. Research Council asks FDA to extend allowable shelf life for tablets being stored for an emergency. Although the pill can protect against thyroid cancer after an incident, it "will not protect the body against other types of radioactive isotopes released during nuclear reactor incidents or those likely to be used in a so-called dirty bomb," authors note...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS096251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel